<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335097">
  <stage>Registered</stage>
  <submitdate>1/02/2010</submitdate>
  <approvaldate>4/02/2010</approvaldate>
  <actrnumber>ACTRN12610000120077</actrnumber>
  <trial_identification>
    <studytitle>International Sarcoma Kindred Study: Identification of inherited risk in individuals with sarcoma</studytitle>
    <scientifictitle>Identification of inherited risk in individuals with sarcoma to aid in the creation of a research resource consisting of biospecimens and associated data</scientifictitle>
    <utrn>U1111-1113-4959</utrn>
    <trialacronym>ISKS</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>sarcoma</healthcondition>
    <healthcondition>genetic mutations</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Sarcoma (also see 'Bone') - soft tissue</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will provide a blood sample (&amp; tissue sample if uncompromised by pre-operative treatment at the time of surgery) and health and epidemiological information once upon enrolment.  The study is anticipated to be ongoing.</interventions>
    <comparator>Matched individuals with no incidence of cancer</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Creation of a research resource consisting of biospecimens and associated clinical data and information from 3000 individuals and their families</outcome>
      <timepoint>At 7 years from commencement of the study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Development of clinically useful population based criteria for stratifying genetic or hereditary risk for adult-onset sarcoma</outcome>
      <timepoint>At 7 years from commencement of the study</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Mapping genetic mutations in patients with adult-onset sarcoma using linkage analysis and next generation sequencing</outcome>
      <timepoint>At 2-5 years from the commencement of the study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of community attitudes to genetic research and testing in the setting of sarcoma using a questionnaire</outcome>
      <timepoint>At 2-3 years from the commencement of the study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All those diagnosed with sarcoma are eligible for inclusion.  Controls must be age matched within 5 years of the proband, be older than or equal to 18 years of age, not have had a cancer diagnosis and not be a blood relative.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Controls must be older than or equal to 18 years of age</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2009</anticipatedstartdate>
    <actualstartdate>8/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>3000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA,VIC</recruitmentstate>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic Of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Sarcoma Study Group</primarysponsorname>
    <primarysponsoraddress>Peter MacCallum Cancer Centre
Level 2 10 St Andrews Place
East Melbourne
VIC 3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Rainbows for Kate Foundation</fundingname>
      <fundingaddress>C/- ASSG
Peter MacCallum Cancer Centre
St Andrew's Place
East Melbourne
Vic 3002</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Victorian Cancer Agency</fundingname>
      <fundingaddress>GPO Box 4541 (Level 19)
MELBOURNE  VIC  3001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Liddy Shriver Sarcoma Initiative</fundingname>
      <fundingaddress>New York</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Isabelle Ray-Coquard</othercollaboratorname>
      <othercollaboratoraddress>Centre Leon Berard, 28 Prom. Lea et Napolean Bullukian, 69008 Lyon, France</othercollaboratoraddress>
      <othercollaboratorcountry>France</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Winette van der Graaf</othercollaboratorname>
      <othercollaboratoraddress>Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK</othercollaboratoraddress>
      <othercollaboratorcountry>United Kingdom</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Joshua Schiffman</othercollaboratorname>
      <othercollaboratoraddress>Hunstman Cancer Institute, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA</othercollaboratoraddress>
      <othercollaboratorcountry>United States of America</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Robert Maki</othercollaboratorname>
      <othercollaboratoraddress>Mount Sinai Hospital, One Gustave L. Levy Place
New York, NY 10029-6574, USA</othercollaboratoraddress>
      <othercollaboratorcountry>United States of America</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Ajay Puri</othercollaboratorname>
      <othercollaboratoraddress>Tata Memorial Hospital, Dr E Borges Road, Parel, Mumbai, Maharashtra 400012, India</othercollaboratoraddress>
      <othercollaboratorcountry>India</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>JinHee Ahn</othercollaboratorname>
      <othercollaboratoraddress>Asan Medical Centre, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea</othercollaboratoraddress>
      <othercollaboratorcountry>Korea, Republic Of</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to identify inherited risk in individuals with sarcoma to aid in the creation of a research resource consisting of biospecimens and associated data.
Who is it for?
You may be eligible to join this study if you have been diagnosed with sarcoma. 
Study details
Participants will be identified at key sarcoma clinics, asked to complete a questionnarie and provide biospecimens (blood and tissue). The biospecimens will be stored indefinitely in a tissue bank to be utilised by researchers investigating genetic factors contributing to cancer. Information obtained from the questionnaire will be used to ascertain the family history of cancer and other factors that may contribute to development of the disease. The ongoing nature of the project will enable continual provision of important practical information for clinicians and patients leading to more favourable outcomes.
Sarcomas contribute disproportionately to cancer burden in our community, because they affect the young, treatment is costly and prolonged and morbidity and mortality is high. Genetic factors appear important in sarcomas, although they have not been well studied for the adult population. Early detection by identifying those at risk may lead to better prognoses. This project aims to create a vital research resource to enable further study into the genetic factors contributing to the hereditary risk of developing sarcoma. </summary>
    <trialwebsite>www.australiansarcomagroup.org/sarcomakindredstudy/</trialwebsite>
    <publication>Downing et al.  An increased incidence of Hodgkins lymphoma in patients with adult-onset sarcoma.  Clinical Sarcoma Research 2012, 2:1
Young et al.  The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research.  Clinical Sarcoma Research 2013, 3:11
Savage et al.  Genome-wide association study identifies two susceptibility loci for osteosarcoma.  Nature Genetics 2013, 45(7):799-803
Mitchell et al.  High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort.  PLOS One 2013, 8(7): e69026
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre Human Research Ethics Committee</ethicname>
      <ethicaddress>Peter MacCallum Cancer Centre
St Andrew's Place
East Melbourne
VIC 3002</ethicaddress>
      <ethicapprovaldate>14/04/2009</ethicapprovaldate>
      <hrec>9/11/2010</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>NSW Population &amp; Health Services Research Ethics Committee</ethicname>
      <ethicaddress>Cancer Institute NSW
Australian Technology Park
Biomedical Building
PO Box 41
Alexandria
NSW 1435</ethicaddress>
      <ethicapprovaldate>6/08/2009</ethicapprovaldate>
      <hrec>HREC/09/CIPHS/34</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Princess Alexandra Hospital
Ipswich Road
Woolloongabba
QLD 4102</ethicaddress>
      <ethicapprovaldate>16/06/2009</ethicapprovaldate>
      <hrec>2009/104</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>UnitingCare Health Human Research Ethics Committee</ethicname>
      <ethicaddress>PO Box 499
Toowong
QLD 4066</ethicaddress>
      <ethicapprovaldate>26/06/2009</ethicapprovaldate>
      <hrec>0918</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mandy Ballinger</name>
      <address>The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, NSW 2010</address>
      <phone>+61 417 546042</phone>
      <fax>+61 2 9355 5872</fax>
      <email>m.ballinger@garvan.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mandy Ballinger</name>
      <address>The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, NSW 2010</address>
      <phone>+61 2 9355 5806</phone>
      <fax>+61 2 9355 5872</fax>
      <email>m.ballinger@garvan.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mandy Ballinger</name>
      <address>The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, NSW 2010</address>
      <phone>+61 417 546042</phone>
      <fax>+61 2 9355 5872</fax>
      <email>m.ballinger@garvan.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>David Thomas</name>
      <address>The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria Street, Darlinghurst, NSW 2010</address>
      <phone>61 2 9355 5770</phone>
      <fax />
      <email>d.thomas@garvan.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>